Comments on: Hot Stocks: Pfizer-Wyeth Merger Underscores That Bigger isn't Better, Takeover Expert Basenese Says http://moneymorning.com/2009/02/02/pfizer/ Global Investment News Mon, 13 Feb 2012 18:41:47 +0000 hourly 1 http://wordpress.org/?v=3.3.1 By: The Market's Safest Sector Also Has Enormous Potential to Rise http://moneymorning.com/2009/02/02/pfizer/comment-page-1/#comment-12712 The Market's Safest Sector Also Has Enormous Potential to Rise Fri, 05 Feb 2010 16:22:10 +0000 http://www.moneymorning.com/?p=4633#comment-12712 [...] one of the biggest vaccines businesses in the drug world. It’s part of the reason the company recently fetched a $68 billion buyout offer from Pfizer. Dutch biopharma player Crucell NV (ADR: CRXL) is the top remaining independent vaccine players in [...] [...] one of the biggest vaccines businesses in the drug world. It's part of the reason the company recently fetched a $68 billion buyout offer from Pfizer. Dutch biopharma player Crucell NV (ADR: CRXL) is the top remaining independent vaccine players in [...]

]]> By: Roche Keeps M&A Party Rolling with $46.8 Billion Deal for Genentech http://moneymorning.com/2009/02/02/pfizer/comment-page-1/#comment-5120 Roche Keeps M&A Party Rolling with $46.8 Billion Deal for Genentech Wed, 18 Mar 2009 16:26:52 +0000 http://www.moneymorning.com/?p=4633#comment-5120 [...] expert who is the editor of the Takeover Trader and White Cap Report newsletters. “I think it would have been a more prudent use of capital considering the company’s checkered history of buying big companies – such as [...] [...] expert who is the editor of the Takeover Trader and White Cap Report newsletters. “I think it would have been a more prudent use of capital considering the company’s checkered history of buying big companies – such as [...]

]]> By: Roche Strikes $46.8 Billion Deal for Genentech | Jutia Group http://moneymorning.com/2009/02/02/pfizer/comment-page-1/#comment-5119 Roche Strikes $46.8 Billion Deal for Genentech | Jutia Group Fri, 13 Mar 2009 14:09:04 +0000 http://www.moneymorning.com/?p=4633#comment-5119 [...] expert who is the editor of the Takeover Trader and White Cap Report newsletters. “I think it would have been a more prudent use of capital considering the company’s checkered history of buying big companies – such as [...] [...] expert who is the editor of the Takeover Trader and White Cap Report newsletters. “I think it would have been a more prudent use of capital considering the company’s checkered history of buying big companies – such as [...]

]]> By: Stock market investing | The Market’s Safest Sector Also Has Enormous Potential to Rise - Contrarian Stock Market Investing News - Featuring Bargain Stocks http://moneymorning.com/2009/02/02/pfizer/comment-page-1/#comment-5115 Stock market investing | The Market’s Safest Sector Also Has Enormous Potential to Rise - Contrarian Stock Market Investing News - Featuring Bargain Stocks Sat, 07 Feb 2009 00:21:54 +0000 http://www.moneymorning.com/?p=4633#comment-5115 [...] has one of the biggest vaccines businesses in the drug world. It’s part of the reason the company recently fetched a $68 billion buyout offer from Pfizer. Dutch biopharma player Crucell NV (ADR: CRXL) is the top remaining independent vaccine players in [...] [...] has one of the biggest vaccines businesses in the drug world. It’s part of the reason the company recently fetched a $68 billion buyout offer from Pfizer. Dutch biopharma player Crucell NV (ADR: CRXL) is the top remaining independent vaccine players in [...]

]]> By: The Market's Safest Sector Also Has Enormous Potential to Rise http://moneymorning.com/2009/02/02/pfizer/comment-page-1/#comment-5116 The Market's Safest Sector Also Has Enormous Potential to Rise Fri, 06 Feb 2009 10:54:48 +0000 http://www.moneymorning.com/?p=4633#comment-5116 [...] one of the biggest vaccines businesses in the drug world. It’s part of the reason the company recently fetched a $68 billion buyout offer from Pfizer. Danish biopharma player Crucell NV (ADR: CRXL) is the top remaining independent vaccine players in [...] [...] one of the biggest vaccines businesses in the drug world. It's part of the reason the company recently fetched a $68 billion buyout offer from Pfizer. Danish biopharma player Crucell NV (ADR: CRXL) is the top remaining independent vaccine players in [...]

]]> By: Busy Man Fitness http://moneymorning.com/2009/02/02/pfizer/comment-page-1/#comment-5118 Busy Man Fitness Tue, 03 Feb 2009 00:13:03 +0000 http://www.moneymorning.com/?p=4633#comment-5118 What will happen to these companies when healthcare becomes socialized? I can't but wonder if the dawn of biotech is long gone! What will happen to these companies when healthcare becomes socialized?

I can't but wonder if the dawn of biotech is long gone!

]]> By: The $68 Billion Pfizer-Wyeth Deal Won't Revive the Moribund Merger Market http://moneymorning.com/2009/02/02/pfizer/comment-page-1/#comment-5117 The $68 Billion Pfizer-Wyeth Deal Won't Revive the Moribund Merger Market Mon, 02 Feb 2009 10:37:37 +0000 http://www.moneymorning.com/?p=4633#comment-5117 [...] Pfizer, a company with strong cash flow and lots of cash on its balance sheet, did get $22.5 billion in financing for the Wyeth buyout, but others are unlikely to get the same terms. The drug company has a rare, stellar "AAA" credit rating from Standard & Poor’s Inc. [Editor’s Note: For a related story that studies the problems associated with the Pfizer-Wyeth merger that appears elsewhere in today’s issue of Money Morning, please click here]. [...] [...] Pfizer, a company with strong cash flow and lots of cash on its balance sheet, did get $22.5 billion in financing for the Wyeth buyout, but others are unlikely to get the same terms. The drug company has a rare, stellar "AAA" credit rating from Standard & Poor’s Inc. [Editor’s Note: For a related story that studies the problems associated with the Pfizer-Wyeth merger that appears elsewhere in today’s issue of Money Morning, please click here]. [...]

]]>